ARA-290, also called cibinetide, is an 11-amino-acid synthetic peptide copied from the helix B region of erythropoietin and built to trigger that hormone's tissue-protective signaling without raising red cell mass. The published human record consists of small placebo-controlled phase 2 trials in sarcoidosis-associated small fiber neuropathy and in type 2 diabetes, each running 28 days and reporting improved neuropathic symptom scores alongside increased corneal nerve fiber measures. No regulator has approved it for any indication, and material sold outside a trial is an unapproved investigational substance with no verified identity, purity, or sterility.
ARA-290 has been studied in humans only through 28-day phase 2 trials at 1 to 8 mg daily, and it holds no marketing approval from the FDA, the EMA, or any other national regulator.
Erythropoietin is a 165-amino-acid glycoprotein, and only a small outward-facing patch of it carries the tissue-protective signal. ARA-290 reproduces that patch alone, an 11-residue sequence taken from the aqueous face of helix B, a surface that plays no part in binding the classical erythropoietin receptor. Separating the protective signal from the red-cell-forming one was the design objective from the outset, because large randomized trials of erythropoietin pushed toward normal hemoglobin recorded increased death, cardiovascular events, stroke, and thrombosis.
ARA-290 is the 11-amino-acid sequence QEQLERALNSS drawn from the aqueous face of erythropoietin's helix B, and cibinetide is the international nonproprietary name for that same molecule.
The receptor this peptide targets is largely absent from healthy tissue. The innate repair receptor is described as a heteromer of an erythropoietin receptor subunit paired with the beta common receptor CD131, the signaling subunit shared by the GM-CSF, interleukin-3, and interleukin-5 receptors, and its assembly is induced locally by metabolic stress, hypoxia, and inflammatory signaling. That restriction carries the selectivity argument: ARA-290 binds this complex far more weakly than erythropoietin binds its classical receptor, and weak affinity matters less when the target appears only where tissue is already injured.
The innate repair receptor is a heteromer of an erythropoietin receptor subunit and the beta common receptor CD131 that assembles only on stressed or injured cells, and its precise stoichiometry remains under active investigation rather than settled.
Activating the classical erythropoietin receptor takes a ligand carrying two distinct binding faces, since the receptor is a homodimer that must be bridged at both subunits at once. ARA-290 reproduces only one of those faces, so it cannot bridge the dimer at any dose. Trials measured the consequence rather than assuming it, tracking hemoglobin, hematocrit, reticulocyte counts, and platelets across dosing periods of up to a month.
| Criteria | Erythropoietin | ARA-290 |
|---|---|---|
| Receptor engaged | Classical homodimer plus innate repair receptor | Innate repair receptor only |
| Binding faces on the ligand | Two, one high and one lower affinity | One |
| Red cell parameters | Raises hemoglobin and hematocrit | No meaningful change over 28 days |
| Documented vascular risk | Boxed warning covering death, stroke, thrombosis | Not observed in published trials |
Published ARA-290 trials measured hemoglobin, hematocrit, reticulocyte, and platelet counts over dosing periods of up to 28 days and reported no meaningful change, which is the empirical basis for calling the peptide non-erythropoietic in the populations and durations studied so far.
Small fiber neuropathy affects a substantial minority of people with sarcoidosis, and its burning pain, autonomic symptoms, and fatigue do not track with granulomatous disease burden, so immunosuppression aimed at the sarcoidosis often leaves the neuropathy untouched. That therapeutic gap is what the ARA-290 program was built to test. The evidence that exists runs to two placebo-controlled phase 2 studies enrolling tens of patients each, not hundreds.
The largest published ARA-290 trial in sarcoidosis-associated small fiber neuropathy enrolled 64 patients for 28 days, and its corneal nerve fiber gain in the 4 mg group has not been replicated at any larger scale.
The cornea is the most densely innervated tissue in the body, and its small unmyelinated fibers can be imaged non-invasively in minutes, which is why corneal confocal microscopy became the objective endpoint in this program. Investigators counted fibers and measured branch density and total fiber length before and after dosing, reporting increases in treated groups where placebo groups showed none. No dedicated trial in neuropathic corneal pain has been published, and the corneal findings come from the sarcoidosis studies, where those measures were endpoints in patients who also had neuropathic pain.
| Criteria | Corneal confocal microscopy | Skin punch biopsy |
|---|---|---|
| Invasiveness | Non-invasive imaging | Tissue removed from the leg |
| Time to result | Minutes at the device | Laboratory scoring after processing |
| Measure reported | Fiber density, branch density, total fiber length | Intraepidermal nerve fiber density |
| Known weakness | Operator, device, and image-selection variability | Sampling limited to the biopsy site |
Corneal nerve fiber measures in the ARA-290 trials stand as supportive objective evidence that something structural changed, not as a validated surrogate for clinical benefit, and no dedicated ARA-290 trial in neuropathic corneal pain exists in the published record.
Diabetes is the most common cause of small fiber neuropathy worldwide, which made it the obvious second target. Placebo-controlled work in people with type 2 diabetes and neuropathic symptoms over a 28-day course echoed the sarcoidosis findings, with improved patient-reported symptom scores and increased corneal nerve fiber measures relative to placebo. The metabolic readings were the unexpected part, and they rest on small studies rather than on a trial designed to test them.
The hemoglobin A1c and lipid changes reported in the type 2 diabetes work come from small 28-day studies, and no dedicated metabolic trial of ARA-290 has been run to test the hypothesis on its own terms.
Published human studies converge on a narrow range, all of it inside trial protocols. Sarcoidosis and diabetes studies used daily subcutaneous injection across 28 days at 1 to 8 mg, while an earlier randomized pilot used 2 mg intravenously three times weekly for four weeks. Clear dose separation never emerged, a result at least consistent with a receptor present only on injured tissue and therefore saturable at low exposure, though the samples were far too small to map a dose-response curve.
Every published ARA-290 dose was given inside a protocol carrying verified drug identity and purity, sterile preparation, screened participants, defined exclusion criteria, and physician monitoring, none of which accompanies research-chemical material.
Adverse events across the published controlled trials were mostly mild and did not separate meaningfully from placebo, with injection site reactions the most commonly described complaint. Anti-drug antibody formation was not flagged as a problem, though exposure durations ran short enough that a late immune response would not necessarily have surfaced. That record is thin rather than reassuring, since roughly 170 participants dosed for about a month cannot detect uncommon serious events, and long-term data do not exist.
Total published human exposure to ARA-290 amounts to roughly 170 participants dosed for about 28 days, a base too small to detect uncommon serious adverse events and carrying no long-term follow-up at all.
No regulator anywhere has approved ARA-290 for any indication, and the published record stops at phase 2. The compound holds orphan drug designation tied to sarcoidosis, a status routinely presented in marketing as though it were a form of approval. Designation means a regulator agreed the target condition is rare; approval means a regulator reviewed evidence of safety and efficacy and permitted marketing.
| Criteria | Orphan drug designation | Marketing approval |
|---|---|---|
| What the regulator judged | The target condition is rare | Safety and efficacy evidence is sufficient |
| Evidence required | Rarity and a plausible rationale | Completed phase 3 trials and a full safety database |
| What it grants | Fee reductions and possible market exclusivity | Lawful marketing for the approved indication |
| ARA-290 status | Granted in connection with sarcoidosis | Not granted by any regulator |
ARA-290 holds orphan drug designation for sarcoidosis but no marketing approval from the FDA, the EMA, or any other regulator, which makes it an unapproved new drug wherever it is offered for human use.
Standard care for small fiber neuropathy is almost entirely symptomatic, and none of it restores lost nerve fibers. The ARA-290 claim sits in a different category, since the corneal imaging data point toward structural regeneration rather than pain masking. The gap between those categories is evidentiary rather than conceptual: established agents carry large randomized programs, regulatory review, and years of post-marketing surveillance, while ARA-290 has a handful of small phase 2 studies.
No approved treatment for small fiber neuropathy restores lost nerve fibers, and ARA-290's regenerative signal rests on a handful of small phase 2 studies rather than the adequately powered replication on clinically meaningful endpoints that would be required to change practice.
Educational use only. This article describes what the published scientific and clinical literature reports about ARA-290. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
